SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Themis Medicare soars on commencing supply of Diclofenac Topical Gel to Novartis

16 Jan 2014 Evaluate

Themis Medicare is currently trading at Rs. 70.00, up by 2.10 points or 3.09% from its previous closing of Rs. 67.90 on the BSE.

The scrip opened at Rs. 69.70 and has touched a high and low of Rs. 71.25 and Rs. 68.00 respectively. So far 1825 shares were traded on the counter.

The BSE group 'T' stock of face value Rs. 10 has touched a 52 week high of Rs. 89.00 on 22-Jan-2013 and a 52 week low of Rs. 40.00 on 10-Oct-2013.

Last one week high and low of the scrip stood at Rs. 73.90 and Rs. 65.75 respectively. The current market cap of the company is Rs. 54.74 crore.

The promoters holding in the company stood at 69.89% while Institutions and Non-Institutions held 3.35% and 26.76% respectively.

Themis Medicare has commenced supply of Diclofenac Topical Gel using TPM Transdermal Drug Delivery System in finished dosage pharmaceutical form to Novartis India (Novartis) as per agreement entered with them on March 26, 2013. The board of directors at its meeting held on January 15, 2014 has taken the note of it.

Themis Medicare is also engaged in supplying its research formulations to well known Pharmaceutical companies in India namely Alkem Lab, Fulford, Intas Pharmaceuticals, IPCA Lab., Cadila Healthcare, Aristo Pharma, Mankind Pharma, Shreya Lifesciences, Nicholas Piramal, Unichem Lab, etc.

Themis Medicare Share Price

89.50 -0.75 (-0.83%)
20-Apr-2026 11:02 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1677.10
Dr. Reddys Lab 1238.25
Cipla 1238.70
Zydus Lifesciences 941.50
Lupin 2327.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×